KKL-40

KKL-40 is a small molecule inhibitor that targets the trans-transcription process and is effective against methicillin-sensitive and -resistant Staphylococcus aureus (S. aureus) as well as other Gram-positive pathogens including vancomycin-resistant Enterococcus faecium, Bacillus subtilis, and Streptococcus pyogenes. KKL-40 synergizes with the human antimicrobial peptide LL-37 to inhibit S. aureus, but does not synergize with other antibiotics such as daptomycin, kanamycin, or erythromycin. Trans-transcription is an extreme form of recoding, and KKL-40 inhibits trans-transcription but is nontoxic to HeLa cells[1].

Product Specifications

CAS Number

[865285-47-8]

Product Name Alternative

Hydroxytolbutamide

UNSPSC

12352005

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/kkl-40.html

Purity

95.70

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

O=C(NC1=NN=C(C2=CC=C(F)C=C2)O1)C3=CC=CC(C(F)(F)F)=C3

Molecular Formula

C16H9F4N3O2

Molecular Weight

351.26

References & Citations

[1]A Small Molecule Inhibitor of Trans -Translation Synergistically Interacts with Cathelicidin Antimicrobial Peptides to Impair Survival of Staphylococcus aureus.